サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439888

感染症診断 - 世界市場の考察、競合情勢、市場予測（2030年）

Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
感染症診断 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の感染症診断の市場規模は、2022年に385億2,000万米ドル、2030年までに481億米ドルに達し、予測期間中（2022年～2028年）にCAGRで3.80%の成長が見込まれます。市場は、COVID-19、マラリア、腸チフスなどの感染症の流行、伝染病やパンデミックの発生の増加、エンドユーザーに対する感染症診断の安全性、入手性、使いやすさの向上への注目の高まりなどの要因によって活況を呈する見通しであり、これらが予測期間（2024年～2030年）の大きな収益成長につながると見込まれています。

感染症診断の市場力学

感染症診断市場の注目すべき促進要因のうち、感染症の流行は市場の重大な促進要因となっています。例えば、世界保健機関（WHO）（2022）によると、2020年にヒト免疫不全ウイルス（HIV）患者は世界で約3,770万人に上りました。HIVの診断検査の1つに核酸検査（NAT）があり、通常、静脈から血液を採取してウイルスの有無を検査します。この検査では、血液サンプル中のウイルス量も測定します。

さらに、世界中で伝染病やパンデミックの発生が増加していることも、感染症診断市場の成長を後押ししています。例えば、前例のないCOVID-19パンデミックの発生は、世界がこれまでに直面したもっとも危険な課題の1つとなっています。その結果、世界中で深刻な健康被害と社会経済的影響を伴う人道的危機が発生しました。WHO（2022）によると、2020年末までに世界で424万9,488例のCOVID-19が確認され、2022年末までに約1,012万4,070例が確認されています。COVID-19の原因物質であるSARS-CoV-2ウイルスの検出には、定量またはリアルタイム逆転写ポリメラーゼ連鎖反応（qRT-PCRまたはrRT-PCR）、イムノアッセイなどの診断技術が採用されています。

感染症診断市場の成長をもたらしているもう1つの主な要因が、マラリアの流行です。例えば、世界保健機関（WHO）の最新のデータによると、2020年に世界で約2億4,100万人がマラリアに罹患していました。ギムザ染色による患者の血液検体の顕微鏡検査は、マラリアを確認する「ゴールドスタンダード」の方法と考えられています。迅速診断検査は、マラリアの診断に代わる迅速な方法です。

しかし、輸送や保管中に血液サンプルが汚染されるリスクや、熟練した採血者の不足、診断検査の高いコストが、感染症診断市場の成長抑制要因として作用する可能性があります。

感染症診断市場は、パンデミックの初期段階においてCOVID-19の拡大を防止するために必要な措置としてロックダウンが実施され、定期的な診断検査が中止されたため、市場成長が短期的に抑制されたことが報告されています。また、ロックダウンにより診断キットの製造や供給などにも影響が出たため、市場はさらに縮小しました。しかしその後、COVID-19患者の急増により、COVID-19検査とその他の呼吸器疾患検査の需要が増加し、感染症診断市場は若干改善しました。さらに、その他の感染症診断検査などの活動が医療部門を含む各産業で再開されたことで、2024年～2030年の予測期間中、感染症診断市場は活況にあります。

感染症診断市場のセグメント分析

感染症診断市場の技術セグメントでは、イムノアッセイカテゴリが予測期間（2024年～2030年）に市場の収益において大きな成長を記録すると予測されています。

これは、イムノアッセイがその他の診断検査よりも優れた診断機能を有するためと考えられます。イムノアッセイは抗原抗体反応に基づくため、感染症の検出において高感度かつ特異的です。

イムノアッセイは、その他の診断方法よりも利用しやすく、使いやすく、迅速な診断が可能です。また、イムノアッセイは現在感染症診断に利用されているハイテク機器に比べてコストが低いです。

当レポートでは、世界の感染症診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 感染症診断市場レポートのイントロダクション

第2章 感染症診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 感染症診断市場の主な要因の分析

  • 感染症診断市場の促進要因
    • 感染症の流行
    • 複数の診断検査の利用可能性
    • 伝染病やパンデミックの発生の増加
  • 感染症診断市場の抑制要因と課題
    • 輸送中および保管中のサンプル汚染のリスク
    • 診断検査の高いコスト
  • 感染症診断市場の機会
    • AIの使用などの技術の進歩
    • 迅速診断キットの利用可能性と入手性の向上

第5章 感染症診断市場のポーターのファイブフォース分析

第6章 感染症診断市場に対するCOVID-19の影響分析

第7章 感染症診断市場のレイアウト

  • タイプ別
    • 製品
    • サービス
  • 技術別
    • 遺伝物質に基づく検査
    • イムノアッセイ
    • 微生物培養
    • その他
  • 用途別
    • ウイルス性疾患
    • 細菌性疾患
  • エンドユーザー別
    • 病院
    • 診断検査室
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 感染症診断市場：世界の企業シェア分析 - 主要3～5社

第9章 感染症診断市場の企業と製品のプロファイル

  • BD
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • bioMerieux SA
  • QIAGEN
  • DiaSorin S.p.A
  • Meridian Bioscience, Inc.
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • Cepheid
  • Siemens Healthcare GmbH
  • Ortho Clinical Diagnostics
  • Biocare Medical, LLC
  • Bruker
  • Cardinal Health
  • Chembio Diagnostics, Inc
  • Novacyt
  • Trinity Biotech
  • OJ-Bio Limited

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Infectious Disease Diagnostics Market
  • Table 3: Infectious Disease Diagnostics Market in Global (2021-2030)
  • Table 4: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
  • Table 5: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
  • Table 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
  • Table 7: Infectious Disease Diagnostics Market in Global by End-user (2021-2030)
  • Table 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
  • Table 9: Infectious Disease Diagnostics Market in North America (2021-2030)
  • Table 10: Infectious Disease Diagnostics Market in North America by Country (2021-2030)
  • Table 11: Infectious Disease Diagnostics Market in the US (2021-2030)
  • Table 12: Infectious Disease Diagnostics Market in Canada (2021-2030)
  • Table 13: Infectious Disease Diagnostics Market in Mexico (2021-2030)
  • Table 14: Infectious Disease Diagnostics Market in Europe (2021-2030)
  • Table 15: Infectious Disease Diagnostics Market in Europe by Country (2021-2030)
  • Table 16: Infectious Disease Diagnostics Market in France (2021-2030)
  • Table 17: Infectious Disease Diagnostics Market in Germany (2021-2030)
  • Table 18: Infectious Disease Diagnostics Market in the United Kingdom (2021-2030)
  • Table 19: Infectious Disease Diagnostics Market in Italy (2021-2030)
  • Table 20: Infectious Disease Diagnostics Market in Spain (2021-2030)
  • Table 21: Infectious Disease Diagnostics Market in Russia (2021-2030)
  • Table 22: Infectious Disease Diagnostics Market in Rest of Europe (2021-2030)
  • Table 23: Infectious Disease Diagnostics Market in APAC (2021-2030)
  • Table 24: Infectious Disease Diagnostics Market in APAC by Country (2021-2030)
  • Table 25: Infectious Disease Diagnostics Market in China (2021-2030)
  • Table 26: Infectious Disease Diagnostics Market in Japan (2021-2030)
  • Table 27: Infectious Disease Diagnostics Market in India (2021-2030)
  • Table 28: Infectious Disease Diagnostics Market in Australia (2021-2030)
  • Table 29: Infectious Disease Diagnostics Market in South Korea (2021-2030)
  • Table 30: Infectious Disease Diagnostics Market in Rest of APAC (2021-2030)
  • Table 31: Infectious Disease Diagnostics Market in Rest of World (2021-2030)
  • Table 32: Infectious Disease Diagnostics Market in RoW by Region (2021-2030)
  • Table 33: Infectious Disease Diagnostics Market in Middle East (2021-2030)
  • Table 34: Infectious Disease Diagnostics Market in Africa (2021-2030)
  • Table 35: Infectious Disease Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Infectious Disease Diagnostics Market
  • Figure 3: Infectious Disease Diagnostics Market in Global (2021-2030)
  • Figure 4: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
  • Figure 5: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
  • Figure 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
  • Figure 7: Infectious Disease Diagnostics Market in Global by End-User (2021-2030)
  • Figure 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
  • Figure 9: Infectious Disease Diagnostics Market in North America (2021-2030)
  • Figure 10: Infectious Disease Diagnostics Market in North America by Country (2021-2030)
  • Figure 11: Infectious Disease Diagnostics Market in the US (2021-2030)
  • Figure 12: Infectious Disease Diagnostics Market in Canada (2021-2030)
  • Figure 13: Infectious Disease Diagnostics Market in Mexico (2021-2030)
  • Figure 14: Infectious Disease Diagnostics Market in Europe (2021-2030)
  • Figure 15: Infectious Disease Diagnostics Market in Europe by Country (2021-2030)
  • Figure 16: Infectious Disease Diagnostics Market in France (2021-2030)
  • Figure 17: Infectious Disease Diagnostics Market in Germany (2021-2030)
  • Figure 18: Infectious Disease Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 19: Infectious Disease Diagnostics Market in Italy (2021-2030)
  • Figure 20: Infectious Disease Diagnostics Market in Spain (2021-2030)
  • Figure 21: Infectious Disease Diagnostics Market in Russia (2021-2030)
  • Figure 22: Infectious Disease Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 23: Infectious Disease Diagnostics Market in APAC (2021-2030)
  • Figure 24: Infectious Disease Diagnostics Market in APAC by Country (2021-2030)
  • Figure 25: Infectious Disease Diagnostics Market in China (2021-2030)
  • Figure 26: Infectious Disease Diagnostics Market in Japan (2021-2030)
  • Figure 27: Infectious Disease Diagnostics Market in India (2021-2030)
  • Figure 28: Infectious Disease Diagnostics Market in Australia (2021-2030)
  • Figure 29: Infectious Disease Diagnostics Market in South Korea (2021-2030)
  • Figure 30: Infectious Disease Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 31: Infectious Disease Diagnostics Market in Rest of World (2021-2030)
  • Figure 32: Infectious Disease Diagnostics Market in RoW by Region (2021-2030)
  • Figure 33: Infectious Disease Diagnostics Market in Middle East (2021-2030)
  • Figure 34: Infectious Disease Diagnostics Market in Africa (2021-2030)
  • Figure 35: Infectious Disease Diagnostics Market in South America (2021-2030)
  • Figure 36: Market Drivers
  • Figure 37: Market Barriers
  • Figure 38: Marker Opportunities
  • Figure 39: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0565

Infectious Disease Diagnostic Market By Type (Products [Instruments, Reagents And Kits] And Services), By Technology (Genetic Material Based, Immunoassays, Microbial Cultures, And Others) By Application (Viral Diseases, Bacterial Diseses, And Others) By End-User (Hosptials, Diagnostic Labs, And Others) by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to surge in prevalence of infectious diseases and growing concern regarding the incidences of pandemic and epidemics

The global infectious disease diagnostics market was valued at USD 38.52 billion in 2022 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022-2028) to reach USD 48.10 billion by 2030. The infectious disease market is slated to witness prosperity owing to factors such as growing prevalence of infectious diseases such as COVID-19, malaria, typhoid, and others, rising incidences of epidemics and pandemics, and the growing focus on improving the safety, affordability, and usability of infectious disease diagnostics for end-users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2024-2030).

Infectious Disease Diagnostics Market Dynamics:

Among the noteworthy drivers of the infectious disease diagnostics market, the rising prevalence of infectious diseases turns out to be the major factor for accelerating the infectious disease diagnostics market. For instance, according to the World Health Organization (WHO) 2022, globally there were around 37.7 million people suffering from human immunodeficiency virus (HIV) in year 2020. One of the diagnostic test for HIV is Nucleic Acid Test (NAT), where the blood is usually drawn from the vein and tested for the presence of virus. The test also measures the viral load in a blood sample.

Further, rising incidences of epidemics and pandemics across the world is going to boost the market growth for infectious disease diagnostics. For example, the unprecedented outbreak of the COVID-19 pandemic became one of the most dangerous challenges the world has ever faced. It resulted in a humanitarian crisis with severe health and socio-economic consequences across the globe. According to WHO 2022, worldwide there have been 4,249,488 confirmed cases of COVID-19 at the end of 2020 and around 10,124,070 cases at the end of 2022. The diagnostic techniques such as Quantitative or Real-time reverse transcription polymerase chain reaction (qRT-PCR or rRT-PCR), immunoassays, and others were employed in the detection of SARS-CoV-2 virus which is the causative agent for COVID- 19.

Another key factor responsible for the growth of the infectious disease diagnostics market is the increasing prevalence of malaria. For instance, as per the latest data provided by the World Health Organization 2022, globally around 241 million people had suffered from malaria in 2020. The microscopic examination of patients' blood specimen using Giemsa stain is considered as the "gold standard" method for confirmation of malaria. Rapid diagnostic tests are alternative and quick method for the diagnosis of malaria.

However, the risk of blood sample contamination during transport and storage, the lack of skilled phlebotomists and high cost of diagnostic tests may act as restraining factors to the infectious disease diagnostics market growth.

The infectious disease diagnostics market reported a short period of restraint in the market growth during the initial phases of the pandemic due to the implementation of lockdown as necessary measures to prevent the spread of COVID-19 infection leading to the suspension of routine diagnostic checkups. Also, during the initial phases owing to the lockdown, the manufacturing and supply of diagnostic kits, and others were affected leading to further decline in the market. But later owing to the tremendous increase in the COVID-19 cases the demand for COVID- 19 testing along with test for other respiratory diseases increased leading to slight improvement in the infectious disease diagnostics market. Moreover, with the resumption of activities including diagnostic tests for other infectious diseases, and others across industries including the healthcare sector, it has been uplifting for the infectious disease diagnostics market during the forecast period from 2024-2030.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments, Reagents and Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others) Application (Viral, Bacterial, and Others) End-User (Hospitals, Diagnostic Labs, and Others) Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the technology segment of the infectious disease diagnostics market, the immunoassays category is projected to register a significant growth in the revenue of the infectious disease diagnosis market during the forecast period (2024-2030).

This can be ascribed to the superior diagnostic features associated with the immunoassays over other diagnostic tests. Immunoassays are based on antigen-antibody reactions and therefore they are highly sensitive and specific for the detection of infectious diseases.

Immunoassays are more readily available, accessible, easy to use, and have rapid turnaround time when compared to other methods of disease diagnosis. Also, the immunoassays are less costly than high tech instruments which are currently utilized for infectious disease diagnosis.

Although immunoassays are used as confirmatory tests along with other tests for infectious disease diagnosis but in certain diseases such as Lyme disease, syphilis, and others, they are primary means for disease detection.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In November 2020, Hologic, Inc., received U.S. Food and Drug Administration (FDA) approval for its Aptima® HIV-1 Quant Dx assay which is the first dual-claim assay for both diagnosis and viral load monitoring. Therefore, considering the advantages associated with the immunoassays and their growing popularity among the end-users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global infectious disease diagnostics market during the forecast period.

North America is expected to dominate the overall Infectious Disease Diagnostics Market:

Among all the regions, North America is expected to lead in revenue generation of global infectious disease diagnostics market. This can be ascribed to the presence of large patient pool associated with infectious diseases including Sexually transmitted diseases (STSs), TB, and others, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region. According to Centers for Disease Control and Prevention 2022, it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019.

Another factor contributing in the growth of infectious disease diagnostics is the increasing cases of tuberculosis. For instance, as per the Centers for Disease Control and Prevention 2022, there were around 7,860 cases of TB reported in 2022 in the United States. As per the same source, currently around 13 million people are living with latent TB infection in the US. The Mantoux tuberculin skin test (TST) is widely used for the screening of tuberculosis.

Moreover, the presence of key market players including BD, Abbott, and Thermo Fisher Scientific Inc. among others along with continuous regulatory approvals are likely to increase the demand for infectious disease diagnostics.

For instance, in July 2022 DiaSorin received the US FDA 510(k) clearance for LIAISON® MeMed BV® Test which is intended for differentiating between the viral and bacterial infections.

Therefore, along with the presence of large patient pool in the country, the increasing focus of key manufacturers on launching the new products in the market is expected to bolster the growth of the infectious disease diagnostics market in the United States during the forecast period.

Infectious Disease Diagnostics Market Key Players:

Some of the key market players operating in the Infectious Disease Diagnostics Market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMerieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in Infectious Disease Diagnostics Market:

In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.

In December 2022, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

In March 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

Key Takeaways from the Infectious Disease Diagnostics Market Report Study

  • Market size analysis for current infectious disease diagnostics market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the infectious disease diagnostics market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
  • Key companies dominating the global infectious disease diagnostics market.
  • Various opportunities available for the other competitor in the infectious disease diagnostics market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current infectious disease diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target Audience who can be benefited from this Infectious Disease Diagnostics Market Report Study

  • Infectious diseases diagnostic products providers
  • Research organizations and consulting companies
  • Infectious diseases diagnostic -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in infectious diseases diagnostic
  • Various end users who want to know more about the infectious disease diagnostics Market and latest technological developments in the infectious disease diagnostics market.

Frequently Asked Questions for Infectious Disease Diagnostics Market:

1. What are infectious disease diagnostics?

Infectious disease diagnostics comprises of diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

2. What is the market for the global infectious disease diagnostic?

The global infectious disease diagnostics market was valued at USD 38.52 billion in 2022 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022-2028) to reach USD 48.10 billion by 2030.

3. What are the drivers for the global infectious disease diagnostics market?

The infectious disease diagnostics market is slated to witness prosperity owing to factors such as increase in the prevalence of infectious diseases such as COVID-19, and HIV among others, technological advancements such as use of AI, rising incidences of epidemics and pandemics, and the growing focus on improving the safety and usability of infectious disease diagnostics for end users are further expected to result in the appreciable revenue growth in the infectious disease diagnostics market during the forecast period (2024-2030).

4. Who are the key players operating in the global infectious disease diagnostics market?

Some of the key market players operating in the infectious disease diagnostics market includes BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., bioMerieux SA, Abbott, QIAGEN, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC, Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

5. Which region has the highest share in the infectious disease diagnostics market?

North America is expected to dominate the overall infectious disease diagnostics market during the forecast period, 2024 to 2030. This can be ascribed to the presence of large patient pool associated with multiple infectious diseases such as STS, Tuberculosis, HPV, and others, high tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Infectious Disease Diagnostics Market Report Introduction

2. Infectious Disease Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Infectious Disease Diagnostics Market Key Factors Analysis

  • 4.1. Infectious Disease Diagnostics Market Drivers
    • 4.1.1. Increasing prevalence of infectious diseases
    • 4.1.2. Availability of multiple diagnostic tests
    • 4.1.3. Increasing incidences of epidemics and pandemics
  • 4.2. Infectious Disease Diagnostics Market Restraints and Challenges
    • 4.2.1. Risk of sample contamination during transport and storage
    • 4.2.2. High cost of diagnostic tests
  • 4.3. Infectious Disease Diagnostics Market Opportunities
    • 4.3.1. Rising technological advancements such as use of AI
    • 4.3.2. Increasing availability and affordability of rapid diagnostic kits

5. Infectious Disease Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Infectious Disease Diagnostics Market

7. Infectious Disease Diagnostics Market Layout

  • 7.1. By Type
    • 7.1.1. Products
      • 7.1.1.1. Instruments
      • 7.1.1.2. Reagents and Kits
    • 7.1.2. Services
  • 7.2. By Technology
    • 7.2.1. Genetic material based tests
    • 7.2.2. Immunoassays
    • 7.2.3. Microbial cultures
    • 7.2.4. Others
  • 7.3. By Application
    • 7.3.1. Viral diseases
    • 7.3.2. Bacterial diseases
    • 7.3.3. Others
  • 7.4. By End-user
    • 7.4.1. Hospitals
    • 7.4.2. Diagnostic Labs
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.1.2. Canada Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.1.3. Mexico Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.2. Europe
      • 7.5.2.1. France Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.2. Germany Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.3. United Kingdom Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.4. Italy Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.5. Spain Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.6. Russia Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.2.7. Rest of Europe Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.2. Japan Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.3. India Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.4. Australia Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.5. South Korea Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.3.6. Rest of Asia Pacific Infectious Disease Diagnostics Market in USD million (2021-2030)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.4.2. Africa Infectious Disease Diagnostics Market in USD million (2021-2030)
      • 7.5.4.3. South America Infectious Disease Diagnostics Market in USD million (2021-2030)

8. Infectious Disease Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. Infectious Disease Diagnostics Market Company and Product Profiles

  • 9.1. BD
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Bio-Rad Laboratories, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. F. Hoffmann-La Roche Ltd
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Abbott
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. bioMerieux SA
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. QIAGEN
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. DiaSorin S.p.A
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Meridian Bioscience, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Quest Diagnostics
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Thermo Fisher Scientific Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Cepheid
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Siemens Healthcare GmbH
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Ortho Clinical Diagnostics
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Biocare Medical, LLC
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Bruker
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Cardinal Health
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Chembio Diagnostics, Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Novacyt
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Trinity Biotech
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. OJ-Bio Limited
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us